| Literature DB >> 28105284 |
Isamu Sugimoto1, Tohru Kambe2, Tomotaka Okino2, Tetsuo Obitsu2, Nobukazu Ohta2, Taihei Nishiyama2, Akihiro Kinoshita2, Taku Fujimoto2, Hiromu Egashira2, Shinsaku Yamane2, Satoshi Shuto3, Kousuke Tani2, Toru Maruyama2.
Abstract
A novel series of prostaglandin analogues with a seven-membered ring scaffold was designed, synthesized, and evaluated for the functional activation of prostaglandin receptors to identify potent and subtype-selective FP and EP3 dual agonists. Starting from the prostacyclin derivative 5b, a nonselective agonist for prostaglandin receptors, replacement of the core structure with an octahydro-2H-cyclopenta[b]oxepine scaffold led to the discovery of the potent and selective FP and EP3 dual agonist 11b as a lead compound for the development of an antiglaucoma agent.Entities:
Keywords: EP3 receptor; FP receptor; GPCR; Prostaglandin; dual agonist; glaucoma
Year: 2016 PMID: 28105284 PMCID: PMC5238478 DOI: 10.1021/acsmedchemlett.6b00415
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345